Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
- 31 October 2012
- journal article
- review article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 12 (10), 781-789
- https://doi.org/10.1016/s1473-3099(12)70187-1
Abstract
No abstract availableFunding Information
- Canadian Institutes of Health Research (grant CRN-83320)
This publication has 34 references indexed in Scilit:
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine seraVaccine, 2011
- HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protectionVaccine, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Health and Economic Implications of HPV Vaccination in the United StatesThe New England Journal of Medicine, 2008
- Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-AnalysisAmerican Journal of Epidemiology, 2008
- The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical PracticeJNCI Journal of the National Cancer Institute, 2005
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerThe New England Journal of Medicine, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986